Abstract: Provided is a process for production of fucoxanthin and/or polysaccharides from microalgae and the use of purified fucoxanthin thereof in pharmaceutical, cosmetic, nutraceutical and food compositions.
Abstract: Methods for treating and/or preventing periodontal disease with arginine silicate are disclosed. Methods may include the steps of identifying an individual in need of treatment for, or in need of prevention of, periodontal disease and administering an effective amount of an arginine-silicate complex to said individual. Arginine silicate may also be used to ameliorate one or more symptoms of periodontal disease. In some aspects, arginine silicate may be used to restore gum health and/or stop or reverse recession of the gums and/or the loss of gum tissue in the oral cavity.
Abstract: Disclosed is the use of a tumor gene methylation regulator in preparing anti-tumor drugs. Furthermore, the tumor gene methylation regulator can be used as a sensitizer to be combined with a tumor therapeutic drug for preparing anti-tumor drugs.
Abstract: A composition for use in the treatment of rosacea includes a multi-kinase inhibitor that inhibits both a Vascular Endothelial Growth Factor Receptor and a Fibroblast Growth Factor Receptor. A method for treating rosacea for a patient includes inhibiting a Vascular Endothelial Growth Factor Receptor of the patient; and inhibiting a Fibroblast Growth Factor Receptor of the patient.
Abstract: The present invention includes compositions and methods for treating or preventing certain dermal disorders including dermal atrophy, pseudoscars, actinic keratosis, seborrheic or actinic keratoses, lentigines, focal areas of dermal thickening, and coarse wrinkles. In certain embodiments, the compositions useful within the invention comprise a therapeutically effective amount of a mTORC1 inhibitor and a dermatologically acceptable carrier.
Type:
Grant
Filed:
May 21, 2020
Date of Patent:
November 23, 2021
Assignee:
Drexel University
Inventors:
Christian Sell, Timothy Nacarelli, Ashley Azar
Abstract: The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R4 are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.
Abstract: The invention relates to the combination of inhibitors of phosphodiesterase 1 (PDE1) and inhibitors of Neprilysin (NEP) useful for the treatment of certain cardiovascular diseases or related disorders, e.g., hypertension, congestive heart disease, and post-myocardial infarction. In another embodiment, the invention relates to the combination of inhibitors of PDE1 and inhibitors of NEP for the treatment of diseases or disorders characterized by disruption of or damage to various cGMP/PKG mediated pathways in the cardiovascular system (e.g., in cardiac tissue or in arterial smooth muscle).
Abstract: Therapeutic combinations of a MEK inhibitor and a Bruton's tyrosine kinase (BTK) inhibitor are described. In some embodiments, the invention provides pharmaceutical compositions comprising combinations of a MEK inhibitor and a BTK inhibitor and methods of using the pharmaceutical compositions for treating a disease, in particular a cancer.
Type:
Grant
Filed:
March 26, 2019
Date of Patent:
October 26, 2021
Assignee:
Acera Pharma B.V.
Inventors:
Wayne Rothbaum, Brian Lannutti, Allard Kaptein
Abstract: The present invention provides novel compounds that are quinoline foldamers. Such foldamers stabilize and bind to islet amyloid polypeptide (IAPP). In certain embodiments, the quinoline foldamers of the invention are soluble and cross biological membranes without cellular assistance. The present invention further provides novel method of preventing or treating diabetes in a subject in need thereof by administering to the subject an effective amount of at least one quinoline foldamer of the invention. The present invention further provides novel method of preventing or treating a neurodegenerative disease caused by a misfolded and/or unstructured protein in a subject in need thereof by administering to the subject an effective amount of at least one quinoline foldamer of the invention.
Abstract: The present invention includes methods of stabilizing one or more sweet enhancers when they are exposed to a light source as well as liquid compositions containing one or more sweet enhancers and one or more photostabilizers.
Type:
Grant
Filed:
March 13, 2019
Date of Patent:
September 28, 2021
Assignee:
FIREMENICH INCORPORATED
Inventors:
Catherine Tachdjian, Donald Karanewsky, Xiao Qing Tang, Hanghui Liu
Abstract: The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and/or solvate thereof, for use in the prevention and/or the treatment of disorders associated to the inflammation induced by P. acnes, in particular in the prevention and/or the treatment of acne, psoriasis, chronic urticaria, urticaria pigmentosa, cutaneous autoinflammatory diseases, hidradenitis or atopic dermatis.
Type:
Grant
Filed:
July 13, 2017
Date of Patent:
September 14, 2021
Assignees:
Universite de Paris, Assistance Publique—Hopitaux de Paris
Inventors:
Nicolas Dupin, Vincent Calvez, Philippe Grange, Anne-Geneviève Marcelin
Abstract: The present invention relates to topical pharmaceutical compositions of apremilast used for the treatment of psoriasis and/or psoriatic arthritis. It further relates to processes of preparation of the compositions and the method of use for these compositions.
Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver diseases and disorders.
Type:
Grant
Filed:
February 20, 2017
Date of Patent:
September 7, 2021
Assignee:
Novartis AG
Inventors:
Bryan Laffitte, Michael Badman, Jin Chen, Sam Lindgren
Abstract: The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.
Type:
Grant
Filed:
December 4, 2019
Date of Patent:
August 24, 2021
Assignee:
Novartis AG
Inventors:
Therese Di Paolo, Dominik Feuerbach, Baltazar Gomez-Mancilla, Donald Johns
Abstract: The present invention provides a chewable dosage form having a matrix comprising: a combination of active pharmaceutical ingredients which is metformin hydrochloride and sitagliptin or a pharmaceutically acceptable salt thereof; a fully or partially pregelatinized starch, a polyethylene glycol polymer; a lubricant; an emulsifier; a flavoring agent; and a sweetener. The present invention also provides a method of treating diabetes, e.g., non-insulin dependent (Type 2) diabetes mellitus, comprising administering a therapeutically effective amount of the chewable dosage form to a mammalian patient in need thereof.
Abstract: The present invention relates to a method of treatment of movement disorders, comprising administering to a patient in need thereof an effective amount of befiradol, wherein the administering step provides an average patient's maximum plasma concentration of befiradol below 15 ng/mL which occurs more than 4 hours post administration, said method minimizing side effects of dizziness and nausea. Sustained release pharmaceutical compositions that can be used according to this method are also described.
Type:
Grant
Filed:
December 17, 2019
Date of Patent:
August 17, 2021
Assignee:
PIERRE FABRE MEDICAMENT
Inventors:
Bruno Paillard, Laurence Del Frari, Valérie Brunner, Adrian Newman Tancredi, Mark Varney
Abstract: This invention relates to preparations comprising a butyrate salt for enteral administration for use in the treatment of conditions and diseases that are not diseases or conditions of the intestine and/or are associated with systemic inflammation. Preparations comprising a butyrate salt for enteral administration were found useful in the treatment of osteoarthritis, Parkinson's disease, migraine, idiopathic subfertility, hangovers, and gout.
Abstract: Lactams for use in the treatment of skin lesions are described. In particular, lactams for the treatment of chronic wounds, including chronic wounds in patients having diabetes.
Type:
Grant
Filed:
July 13, 2017
Date of Patent:
August 10, 2021
Assignee:
Conopco, Inc.
Inventors:
Neil James Parry, Paolo Pantalone, Paul Williams